This site is intended for health professionals only
Tuesday 25 September 2018
Share |

Topic: Patient care

August 24, 2018

Kathy Oxtoby looks at the effects of antimicrobial resistance across Europe will be if it goes unchecked and investigates what should be done to tackle it
 
It may be a natural phenomenon, but antimicrobial resistance (AMR) has become a global health crisis of similar importance to infectious-disease pandemics, according to the World Health Organization (WHO).
 

July 26, 2018
How will Matt Hancock’s healthcare priorities benefit the NHS?

Last week, health and social care secretary Matt Hancock gave his first speech at West Suffolk Hospital where he revealed three key priorities for the NHS: technology, workforce and prevention.
 
Speaking before the Health and Social Care Committee yesterday, he also gave more information on the work he intends to do.
 
A version of this article first appeared on our sister publication Healthcare Leader
So what do the priorities mean for the health service?
 
Technology focus

June 22, 2018
A report from the charity Cancer Research UK has called on the health service to prepare for a large increase in the number of over 75s with cancer

The number of elderly people developing cancer in the UK is expected to nearly double, hitting almost a quarter of a million a year by 2035, new cancer research has predicted.
 
A report from the charity Cancer Research UK has called on the health service to prepare for a large increase in the number of over 75s with cancer. It stated an expected a rise from some 130,000 elderly cancer patients a year to 234,000, in less than 20 years.
 

May 24, 2018
Despite limited resources to support the project management of some of the new initiatives, the gradual application of faster and safer discharge processes, particularly for vulnerable and frail patients, has started to deliver a more efficient hospital and local health system

The Norfolk and Norwich University Hospital Foundation Trust (NNUH) is responsible for providing a broad range of acute clinical services to a population of around 900,000.

The hospital provides secondary acute care and some specialist tertiary services, and is a centre for professional education, training and healthcare research for the East of England.  

February 28, 2018
There are 7000 rare diseases affecting an estimated 350 million people globally

Amicus Therapeutics is honouring Rare Disease Day today with the launch of Healing Beyond Disease™, a global, Amicus employee-driven initiative inspired by people living with rare diseases and their families.

Healing Beyond Disease is designed to enhance and expand the Company’s support for patients, families and advocacy organisations beyond the Company’s research and development of novel medicines. More information on Healing Beyond Disease is available in an infographic on the Amicus corporate website.

February 23, 2018
The CHAMPION trial is assessing the effectiveness and safety of heat-stable carbetocin versus oxytocin, the current standard of care, for preventing postpartum haemorrhage after vaginal birth

Ferring Pharmaceuticals and MSD, through its MSD for Mothersinitiative, has announced the completion of CHAMPION (Carbetocin Haemorrhage Prevention), a global clinical trial conducted by the Human Reproduction Program (HRP) at the World Health Organization (WHO).

February 22, 2018
Rare Disease Day was established in Europe in 2008 by EURORDIS-Rare Diseases Europe, the organisation representing rare disease patients in Europe, and is now observed in more than 90 nations.

Shire has announced its continuing global education and awareness efforts on Rare Disease Day 2018, to deliver on its commitment to champion those impacted by rare disease, including patients, families and caregivers.

The company is helping to raise awareness about the impact and prevalence of rare diseases, while also listening to and working with an extended community of stakeholders on potential innovative solutions to help reduce the time to diagnosis.

January 16, 2018
Establishment of service has led to decline in number of hospital admissions resulting from MS-related urinary tract infections – which can be potentially catastrophic in MS patients

A multiple sclerosis sufferer who could not face going out because of debilitating bladder and bowel problems caused by her condition says she’s been given a new lease of life thanks to an innovative clinic run by Sheffield Teaching Hospitals NHS Foundation Trust.
 
Janet Blair, who was first diagnosed with the condition at the age of 23, hit "rock bottom" after a flare-up of her condition at the age of 59. The relapse left her with left-sided weakness, foot drop, and bladder and bowel problems.
 

November 27, 2017
Survey highlights need for improved education and standardised referral pathways for oncofertility

Results of a new survey highlight the need for improved education and standardised guidance for oncologists initiating cancer treatment in women who may want to safeguard their fertility.1

September 22, 2017
Four new wristband lines have been launched to complement SATO Europe’s premium Thermal Transfer Line wristband, which has proved popular with both patients and hospital staff

SATO Europe, a global leader in the development of Auto-Identification and labelling solutions, has unveiled a new range of pioneering ID wristbands for the healthcare sector to enhance patient safety, security and comfort.
 
The new range includes the Direct Thermal (DT) Line, Eco Line, Laser Line and RFID Line.
 

September 12, 2016
New report shows at least a fifth of the National Health Service providers’ deficit in 2016- 2017 could be saved if every acute trust implemented clinical care in the home

Increasing the use of clinical care in the home could save the NHS money, enable acute trusts to carry out more elective surgery, and manage more emergency admissions, a new report shows.

The report, There’s no place like home, shows the NHS in England could save a potential 500,000 bed days every year if every acute trust used virtual wards at the same scale as the trusts studied for the report. This could save at least £120 million, or 21% of all NHS providers’ predicted deficit for 2016-2017.1

May 25, 2016
New technology makes incident reporting easy and efficient

Imperial College Healthcare NHS Trust, a provider of acute and specialist health services with 10,000 staff is using Datix software to increase efficiencies within the Trust. Since implementing the latest web-based Datix incident, risk, legal and safety alerts modules, the Trust has increased incident reporting levels which in turn has helped the Trust respond more efficiently to risks, as well as ensuring team learning from incidents.
 

May 17, 2016
A1M Pharma has initiated a research collaboration with global biotherapeutics company CSL Behring to investigate the potential of combining Alpha 1 Microglobulin (A1M) with proteins extracted from the fractionation of human plasma such as hemopexin and haptoglobin

A1M Pharma has initiated a research collaboration with global biotherapeutics company CSL Behring to investigate the potential of combining Alpha 1 Microglobulin (A1M) with proteins extracted from the fractionation of human plasma such as hemopexin and haptoglobin. This collaboration strengthens A1M Pharma’s position in the use of A1M for the treatment of life-threatening diseases with therapies that are based on naturally occurring substances.
 

May 13, 2016
First Fc Fusion therapy approved for haemophilia B in the EU to provide extended protection against bleeds

Swedish Orphan Biovitrum AB (publ) (Sobi™) and Biogen announced that the European Commission (EC) has approved Alprolix® (rFIXFc), their extended half-life therapy, for the treatment of haemophilia B in all 28 European Union (EU) Member States and maintained its orphan designation. Alprolix is the only recombinant factor IX Fc Fusion protein therapy for haemophilia B to offer people in the EU prolonged protection against bleeding episodes with fewer prophylactic injections.

May 5, 2016
New integrated surgical theatres built to improve patient care. State of the art surgical imaging and tissue management technologies installed. Improved hospital efficiencies as part of NHS Five Year Forward View

Olympus Medical is proud to announce their partnership with one of London’s largest and busiest teaching hospitals King’s College Hospital (KCH), with the aim of improving patient care, as well as overall efficiency. Through the partnership two new operating theatres have been created featuring upgraded surgical technologies including Full HD (FHD), 3D and 4K surgical imaging platforms and surgical tissue management system ‘THUNDERBEAT’.

May 5, 2016
New integrated surgical theatres built to improve patient care. State of the art surgical imaging and tissue management technologies installed. Improved hospital efficiencies as part of NHS Five Year Forward View

Olympus Medical is proud to announce their partnership with one of London’s largest and busiest teaching hospitals King’s College Hospital (KCH), with the aim of improving patient care, as well as overall efficiency. Through the partnership two new operating theatres have been created featuring upgraded surgical technologies including Full HD (FHD), 3D and 4K surgical imaging platforms and surgical tissue management system ‘THUNDERBEAT’.

April 20, 2016
EADV launched a Global Call to Action urging policy-makers, employers, workers’ organisations and physicians to protect Europe’s outdoor workers from skin cancer caused by solar UV-radiation

The European Academy of Dermatology and Venereology (EADV) launched a Global Call to Action urging policy-makers, employers, workers’ organisations and physicians to protect Europe’s outdoor workers from skin cancer caused by solar UV-radiation. The Call was launched at a policy debate in the European Parliament, hosted by MEP Nessa Childers (S&D), Vice President of the European Parliamentary Interest Group ‘MEPs Against Cancer’, and co-hosted by MEPs Mr Ole Christensen (S&D) and Mr Jens Gieseke (EPP).

April 20, 2016
Real-world data also demonstrate positive experience with TECFIDERA

Biogen present new TECFIDERA (dimethyl fumarate) research at the 68th annual meeting of the American Academy of Neurology (AAN) in Vancouver, Canada. The data presented supports the value of dimethyl fumarate in the treatment of patients with relapsing-remitting multiple sclerosis (RRMS), and provides additional information supporting the efficacy and safety profile, as well as real-world patient-reported outcomes.1,2,3,4
 
More than half of patients free from disease activity over six years

April 14, 2016
Swedish Orphan Biovitrum AB and collaboration partner Biogen have received a positive opinion from the Committee for Orphan Medicinal Products of the European Medicines Agency recommending the European Commission to maintain the orphan designation for Alprolix®, a recombinant factor IX Fc fusion protein therapy for the treatment of haemophilia B

April 14, 2016
New first-in-class inhaled antibiotic for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adults with Cystic Fibrosis now available in Germany and Denmark

Raptor Pharmaceuticals Corp. announced that Quinsair (levofloxacin nebulizer solution) is now available in Germany and Denmark. Quinsair is the first inhaled fluoroquinolone approved in the European Union for the management of chronic pulmonary infections due to P. aeruginosa in adults with cystic fibrosis (CF).1,2 The product is administered twice-daily, stored at room temperature and has a short administration time.

April 6, 2016
Novel liquid biopsy RAS testing now available to clinical practices for metastatic colorectal cancer (mCRC) patients. The test will help guide physicians to select the most effective treatment for mCRC patients in a timely manner

April 4, 2016
New data presented at the American College of Cardiology shows that patients who develop stress-induced ischaemia (inadequate oxygen flow to the heart) have higher levels of troponin, which are associated with worse long term outcomes.

New data presented at the American College of Cardiology shows that patients who develop stress-induced ischaemia (inadequate oxygen flow to the heart) have higher levels of troponin,1  which are associated with worse long term outcomes.2

Doctors could eventually use this information to prevent serious complications from developing by helping patients manage stress through treatment and therapies.
 

April 4, 2016
First-in-class monoclonal antibody targeting CD38 for the treatment of multiple myeloma

April 4, 2016
If approved, TREVICTA® will be the first treatment for schizophrenia to be administered four times a year and will provide the longest dosing interval available for an antipsychotic medication in the European Union